UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis

Clinical cancer research, 2019-03, Vol.25 (5), p.1462-1471

2019

Link zum Volltext

Verfügbarkeit prüfen

Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers

JAMA oncology, 2023-05, Vol.9 (5), p.606

2023

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Journal of clinical oncology, 2021-08, Vol.39 (24), p.2647-2655

2021

Link zum Volltext

Verfügbarkeit prüfen

Mitotane and the myth of 14 mg/L

The lancet oncology, 2024-01, Vol.25 (1), p.12-15

2024

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

Cancers, 2021-10, Vol.13 (21), p.5415

2021

Link zum Volltext

Verfügbarkeit prüfen

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

Journal of translational medicine, 2019-11, Vol.17 (1), p.386-386, Article 386

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)

Clinical cancer research, 2020-02, Vol.26 (4), p.804-811

2020

Link zum Volltext

Verfügbarkeit prüfen

Review of diagnostic, prognostic, and predictive biomarkers in melanoma

Clinical & experimental metastasis, 2018-08, Vol.35 (5-6), p.487-493

2018

Link zum Volltext

Verfügbarkeit prüfen

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Melanoma research, 2021-02, Vol.31 (1), p.27

2021

Link zum Volltext

Verfügbarkeit prüfen

Lung Transplantation for Pulmonary AL Amyloidosis

Transplantation direct, 2024-03, Vol.10 (3), p.e1577-e1577

2024

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Cancer management and research, 2022-01, Vol.14, p.673-686

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessing the Effect of an Intensive 2-Week Surgical Training and Innovation Program for High-School Students

Journal of surgical education, 2017-11, Vol.74 (6), p.958-967

2017

Link zum Volltext

Verfügbarkeit prüfen

1537 Androgen blockade primes NLRP3 inflammasome in macrophages to induce tumor cell phagocytosis

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1760-A1762

2023

Link zum Volltext

Verfügbarkeit prüfen

Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis

Clinical cancer research, 2023-12, Vol.29 (23), p.4930

2023

Link zum Volltext

Verfügbarkeit prüfen

Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer

Clinical cancer research, 2023-05, Vol.29 (10), p.1952-1968

2023

Link zum Volltext

Verfügbarkeit prüfen

Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e17007-e17007

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer

Oncotarget, 2018-01, Vol.9 (4), p.4375-4384

2018

Link zum Volltext

Verfügbarkeit prüfen

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10004-10004

2020

Link zum Volltext

Verfügbarkeit prüfen

Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time

Journal of drugs in dermatology, 2017-03, Vol.16 (3), p.275

2017

Link zum Volltext

Verfügbarkeit prüfen

Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9506-9506

2019

Link zum Volltext

Verfügbarkeit prüfen

MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies

JCO global oncology, 2023-08, Vol.9 (Supplement_1), p.45-45

2023

Link zum Volltext

Verfügbarkeit prüfen

Victorian Young Planners News and Views: Planning Excellence - open for Nomination

Planning news (Hawthorne, Vic.), 2010-08, Vol.36 (7), p.27

Brian Labadie

2010

Link zum Volltext

Verfügbarkeit prüfen

Victorian Young Planners News and Views

Planning news (Hawthorne, Vic.), 2010-02, Vol.36 (1), p.22

Brian Labadie

2010

Link zum Volltext

Verfügbarkeit prüfen

Victorian Young Planners News and Views

Planning news (Hawthorne, Vic.), 2010-01, Vol.36 (9), p.27

Brian Labadie

2010

Link zum Volltext

Verfügbarkeit prüfen

Victorian Young Planners News and Views

Planning news (Hawthorne, Vic.), 2010-01, Vol.36 (11), p.22

Brian Labadie

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(51)
magazinearticle
(5)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis

Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Mitotane and the myth of 14 mg/L

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)

Review of diagnostic, prognostic, and predictive biomarkers in melanoma

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Lung Transplantation for Pulmonary AL Amyloidosis

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Assessing the Effect of an Intensive 2-Week Surgical Training and Innovation Program for High-School Students

1537 Androgen blockade primes NLRP3 inflammasome in macrophages to induce tumor cell phagocytosis

Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis

Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer

Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial

Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time

Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo)

MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies

Victorian Young Planners News and Views: Planning Excellence - open for Nomination

Victorian Young Planners News and Views

Victorian Young Planners News and Views

Victorian Young Planners News and Views

Suchergebnisse filtern